ATE336231T1 - Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung - Google Patents

Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung

Info

Publication number
ATE336231T1
ATE336231T1 AT02801623T AT02801623T ATE336231T1 AT E336231 T1 ATE336231 T1 AT E336231T1 AT 02801623 T AT02801623 T AT 02801623T AT 02801623 T AT02801623 T AT 02801623T AT E336231 T1 ATE336231 T1 AT E336231T1
Authority
AT
Austria
Prior art keywords
solvent
mixing zone
precipitation
producing crystalline
recirculating
Prior art date
Application number
AT02801623T
Other languages
English (en)
Inventor
James E Hitt
Christopher J Tucker
Jonathan C Evans
Cathy A Curtis
Sonke Svenson
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Application granted granted Critical
Publication of ATE336231T1 publication Critical patent/ATE336231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02801623T 2001-08-29 2002-08-27 Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung ATE336231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31556001P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
ATE336231T1 true ATE336231T1 (de) 2006-09-15

Family

ID=23224987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801623T ATE336231T1 (de) 2001-08-29 2002-08-27 Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung

Country Status (6)

Country Link
US (1) US20030049323A1 (de)
EP (1) EP1423096B1 (de)
AT (1) ATE336231T1 (de)
CA (1) CA2458889C (de)
DE (1) DE60214012T2 (de)
WO (1) WO2003032951A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
CA2523883C (en) * 2003-04-29 2012-01-03 Akzo Nobel N.V. Antisolvent solidification process
DK1631261T3 (da) 2003-05-22 2009-11-09 Applied Nanosystems Bv Fremstilling af små partikler
WO2005051511A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation 有機化合物微粒子の製造方法
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
EP1730516A1 (de) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
US9061027B2 (en) * 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
WO2006028074A1 (ja) * 2004-09-07 2006-03-16 Mitsubishi Chemical Corporation 微粒子化された物質の製造方法および微粒子化された物質
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CA2650395A1 (en) * 2006-04-28 2007-11-08 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
GB0705159D0 (en) * 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
EP2178518A2 (de) * 2007-07-13 2010-04-28 Bend Research, Inc Nanopartikel mit ionisierbaren und schwach wasserlöslichen zellulose-polymeren
EP2240162A4 (de) * 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
JP2011527668A (ja) * 2008-07-11 2011-11-04 ビーエーエスエフ ソシエタス・ヨーロピア 形態改質剤としての両親媒性タンパク質
PE20130045A1 (es) 2010-03-12 2013-01-28 Berg Pharma Llc FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS
EP2618818A4 (de) 2010-09-22 2014-10-29 Map Pharmaceuticals Inc Corticosteroidpartikel und herstellungsverfahren dafür
US20120311822A1 (en) * 2011-06-10 2012-12-13 Culkin Joseph B Solute crystallizing apparatus
KR102058256B1 (ko) 2011-06-17 2020-01-22 버그 엘엘씨 흡입성 약제학적 조성물들
EP2601973A1 (de) 2011-12-09 2013-06-12 Laboratoires SMB SA Trockenpulverformulierung eines Azolderivats zum Inhalieren
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
KR20190101408A (ko) * 2017-01-23 2019-08-30 세이비어 라이프텍 코퍼레이션 활성 성분의 미립자 제조
CN109011674B (zh) * 2018-09-11 2020-08-11 安徽东至广信农化有限公司 一种用于硝基氯苯制备的蒸酸器
EP4041203A1 (de) 2019-10-10 2022-08-17 Bayer Aktiengesellschaft Verfahren zur herstellung eines nanopartikulären wirkstoffs

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US624617A (en) * 1899-05-09 Insecticide
SU1126202A3 (ru) * 1976-05-28 1984-11-23 Институт Фор Атомэнерги (Фирма) Способ непрерывной многостадийной кристаллизации из раствора
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
ES2078447T3 (es) * 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
EP0909205B1 (de) * 1996-07-05 2000-05-17 Haarmann & Reimer Gmbh Kristallisationsvorrichtung und -verfahren
DE19738085C1 (de) * 1997-09-01 1998-12-03 Basf Ag Verfahren zur Herstellung von Feststoffen durch Fällung
US5908589A (en) * 1997-12-08 1999-06-01 Twenty-First Century Research Corporation Methods for separating catalyst from oxidation mixtures containing dibasic acids
EP0930073B1 (de) * 1998-01-14 2004-08-04 National Research Development Corporation of India Verfahren zur Herstellung eines spermiziden Mittels
US6607651B2 (en) * 1998-09-10 2003-08-19 Cws Parts Company Process and system for treating the discharge stream from an ion exchanger
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process
TW526172B (en) * 1999-06-30 2003-04-01 Sumitomo Chemical Co A process for producing pentacyl-type crystalline zeolites and a process for producing ε-caprolactam using the same
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions

Also Published As

Publication number Publication date
EP1423096A1 (de) 2004-06-02
WO2003032951A1 (en) 2003-04-24
DE60214012D1 (de) 2006-09-28
DE60214012T2 (de) 2006-12-21
US20030049323A1 (en) 2003-03-13
CA2458889C (en) 2011-06-21
EP1423096B1 (de) 2006-08-16
CA2458889A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
ATE336231T1 (de) Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
SE9501384D0 (sv) Process for the preparation of respirable particles
PT1180062E (pt) Metodo para a producao de micro e nanoparticulas morfologicamente uniformes utilizando micromisturadores
BR0206164A (pt) Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
EP1862431A8 (de) Herstellungsverfahren für inp-mikroteilchen und mit diesem verfahren hergestellte inp-mikroteilchen-dispersionslösung
DE60029457D1 (de) Verfahren zur herstellung von feinkörnigen medizinischen substanzen
DE69835230D1 (de) Verfahren zur herstellung von nordamerikanischen ginseng fraktionen, enthaltende produkte, und verwendung als immunmodulatoren
ATE199828T1 (de) Verfahren zur konditionierung von substanzen
DE60222695D1 (de) Verfahren zur herstellung von kohlenstoffnanostrukturen
YU66003A (sh) Postupak za izdvajanje hemiceluloza iz biomase koja sadrži hemiceluloze kao i biomasa i hemiceluloze koje se mogu dobiti primenom ovog postupka
DE60027695D1 (de) Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind
ATE228828T1 (de) Verfahren zur herstellung von festen cyclodextrinhaltigen dosierungsformen
DE50205571D1 (de) Verfahren zur Herstellung von direkt tablettierbaren Beta-Mannit
EP1688169A4 (de) Verfahren zur herstellung von feinen teilchen einer organischen verbindung
ATE327737T1 (de) Verfahren zur herstellung von arzneistoffgranulatkörnern, die arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische zubereitungen
PT1583538E (pt) Utilização da 3-metoxi-pregnenolona para a preparação de um medicamento destinado a tratar as doenças neurodegenerativas
DE69625813D1 (de) Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
BR0318104A (pt) Processos para a fabricação de materiais de filtros para água e filtros para água
DE60226637D1 (de) Verfahren zur herstellung von einschlussverbindungen zwischen einem nichtsteroidalen antirheumatikum und betacyclodextrin durch mikrowellenbehandlung
DE602004000665D1 (de) Biologisches Verfahren zur Herstellung eines Hämeisenpräparats und daraus hergestellte Nahrungsmittelprodukte
SG153663A1 (en) Process for the production of biodegradable, functionalised polymer particles and use thereof as pharmaceutical supports
ATE307823T1 (de) 17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
ATE244212T1 (de) Verfahren zur herstellung eines baukörpers
ATE277963T1 (de) Verfahren und vorrichtung zur herstellung von cellulosepartikeln
DE602004031459D1 (de) Verfahren zur herstellung eines medikaments

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties